News & Events

Clinical Program BL8040

Initiation of Phase 1/2 Trial for Novel Treatment in Two Bone Marrow Failure Conditions, hypoplastic myelodysplastic syndrome (hMDS) and aplastic anemia (AA) with BL8040

“BioLineRx Announces Initiation of Phase […]

Positive Clinical Results from First Part of Phase 2 Trial in r/r AML with BL8040

“BioLineRx Announces Positive Clinical Results […]

Initiation of Phase 2b Trial for Novel AML Consolidation Treatment with BL8040

BioLineRx Announces Initiation of Phase […]

Positive Safety and Efficacy Results for Novel Stem-Cell Mobilization Treatment with BL8040

BioLineRx Presented Positive Safety and […]

Pre-Clinical Program

Patent issued in Japan covering the composition and use of novel chemokine binding polypeptides

Biokine Therapeutics Announces Issuance of […]

Biokine Therapeutics Announces Issuance of Chinese Patent covering the composition and use of novel chemokine binding polypeptides

Biokine Therapeutics Announces Issuance of […]

Biokine Therapeutics Announces Issuance of United States Patent covering the use of CXCR4 antagonist for wound healing

Biokine Therapeutics Announces Issuance of […]

Biokine Therapeutics Announces Issuance of United States Patent

Biokine Therapeutics Announces Issuance of […]